|

Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy

RECRUITINGSponsored by Sara A Belal
Actively Recruiting
SponsorSara A Belal
Started2025-08-01
Est. completion2026-08-01
Eligibility
Age25 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07351786

Summary

This study aims to test the impact of new-generation anti-diabetic drugs, such as SGLT2 inhibitors and DPP-4 inhibitors, on the development of diabetic retinopathy (DR). The study hypothesizes that these drugs have protective effects in diabetic retinopathy by delaying its incidence compared to older agents (including metformin) only. Early intervention is critical, as treatment options for advanced stages of DR are limited in terms of their ability to restore impaired vision and their high associated costs. By focusing on delaying the occurrence of diabetic retinopathy, the investigators aim to reduce the burden of DR and improve the quality of life for diabetic patients.

Eligibility

Age: 25 Years+Healthy volunteers accepted
Inclusion Criteria:

* Diagnosed with Type 2 Diabetes for \>5 years
* Using Diabetes medications (metformin, sulfonylureas, SGLT2 inhibitors, DPP-4 inhibitors) for a period of 2-3 years

Exclusion Criteria:

* Gestational Diabetes
* Type 1 Diabetes
* Severe non-proliferative diabetic retinopathy (NPDR) at baseline
* Proliferative diabetic retinopathy (PDR) at baseline
* Pregnant and breastfeeding women

Conditions5

DiabetesDiabetes (DM)Diabetic Retinopathy (DR)Diabetic Retinopathy Associated With Type 2 Diabetes MellitusRetinopathy, Diabetic

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.